Role of autophagy in acute myeloid leukemia therapy

Su-Ping Zhang¹, Yu-Na Niu¹, Na Yuan¹, Ai-Hong Zhang¹, Dan Chao¹, Qiu-Ping Xu¹, Li-Jun Wang¹, Xue-Guang Zhang², Wen-Li Zhao³, Yun Zhao¹ and Jian-Rong Wang¹

Abstract

Despite its dual role in determining cell fate in a wide array of solid cancer cell lines, autophagy has been robustly shown to suppress or kill acute myeloid leukemia cells via degradation of the oncogenic fusion protein that drives leukemogenesis. However, autophagy also induces the demise of acute leukemia cells that do not express the known fusion protein, though the molecular mechanism remains elusive. Nevertheless, since it can induce cooperation with apoptosis and differentiation in response to autophagic signals, autophagy can be manipulated for a better therapy on acute myeloid leukemia.

Key words Autophagy, fusion oncoprotein, acute myeloid leukemia

Autophagy is a ubiquitous process in which “bad” cytosolic molecules, damaged organelles, or invaded pathogens are sequestered within double-membrane vesicles called autophagosomes that deliver their contents to lysosomes for degradation and/or recycling of the resulting macromolecules. Indeed, autophagosomes were found to specifically target damaged mitochondria, peroxisomes, and protein aggregates that lead to DNA damage and genomic instability, thereby maintaining intracellular organelle and protein homeostasis.

Autophagy may also provide nutrients through lysosomal degradation of intracellular components of mitochondrial oxidation. Autophagy is more frequently compromised in solid cancer cells compared with their normal counterparts and acts as a protective mechanism in response to both extracellular and intracellular stress. However, stimulation of autophagy in cancer cells was observed in response to anticancer treatments when enhanced autophagy destroys large proportions of the cytosol and organelles, which causes irreversible cellular atrophy and consequent collapse of vital cellular functions. Heterozygosity for the autophagy-essential gene Beclin1 led to greatly increased rates of tumorigenesis, possibly because of genomic instability when autophagy is reduced. Conversely, autophagy has also been shown to promote the survival of solid cancer cells following stress or nutrient deprivation. Therefore, autophagy can protect cells against death or mediate cellular demise, depending on the autophagic stimuli and cellular context.

Acute myeloid leukemia (AML) is characterized by an accumulation of abnormal hematopoietic progenitor cells, which exhibit the morphology of a certain stage of myeloid differentiation, in the bone marrow and the peripheral blood. The blocked differentiation restrains progenitor cells from maturing and subsequently undergoing apoptosis, and it may also enhance their self-renewal capabilities. Unlike normal hematopoietic cells that require extrinsic signals to maintain metabolism and survival, leukemia cells often express constitutively active oncogenic kinases that promote these processes independent of extrinsic growth factors. When cells receive insufficient growth signals or when oncogenic kinases are inhibited, glucose metabolism decreases and the self-digestive process of autophagy is triggered to degrade bulk cytoplasm and organelles. Given its potential function in metabolism and cell survival, manipulation of autophagy may provide a critical means to eliminate certain type of leukemia cells.

Autophagy in Response to Therapy for PML-RARa[0] t(15,17) Leukemia

Acute promyeloctytic leukemia (APL) is a subtype of AML that can be distinguished from other subtypes by...
distinct cytogenetic and clinical features. More specifically, more than 95% of patients with APL bear the t(15;17) translocation that encodes the PML/RAR fusion protein. This fusion oncprotein suppresses granulocyte development at the promyelocytic stage of differentiation and causes malignant transformation of hematopoietic progenitor cells by acting as a transcriptional repressor of gene expression. All-trans retinoic acid induced disease remission in APL patients by interacting with its ligand, causing proteolytic degradation of the oncprotein and consequent granulocyte differentiation of APL cells. In addition, low-dose arsenic trioxide has been reported to be remarkably effective in treating APL by inducing differentiation, whereas high dose has been reported to trigger apoptosis by causing proteolytic degradation of PML/RARA. The molecular mechanism by which arsenic trioxide degrades PML/RARA involves PML SUMOylation and subsequent polyubiquitination and proteolytic degradation of both PML and PML/RARA by a protein molecule called RNF4. All-trans retinoic acid and arsenic trioxide can act synergistically to cause leukemia regression through distinct mechanisms that lead to PML/RARA degradation, ultimately resulting in clinical remission of APL.

The ubiquitin-proteasome system is largely responsible for degradation of short-lived soluble proteins and misfolded proteins following their labeling with polyubiquitin chains. Previous studies have implicated that the ubiquitin-proteasome system plays an important role in therapy-induced degradation of PML/RARA. SUMO-conjugated PML, RNF4 and components of this system, are corecruited to nuclear compartments called PML nuclear bodies in the presence of arsenic trioxide. Both PML and RARa are targeted primarily to the nucleus, and the PML/RARA chimera is detected mainly within the nucleus of interphase cells. Thus, therapy-induced degradation of PML/RARA is largely thought to occur within the nuclear compartment because PML/RARA, together with ubiquitin and components of the ubiquitin-proteasome system, are recruited to PML nuclear bodies during the first few hours of arsenic trioxide treatment.

The PML/RARA oncprotein is prone to aggregation, which makes it a good substrate for autophagic degradation. Its ability to form protein aggregates is possibly attributable to the PML moiety of the fusion protein, which contains a tripartite motif domain. Together with SUMO-conjugated residues and a SUMO-interacting domain, this tripartite motif in PML facilitates the formation of protein-protein interaction networks. Further, the PML/RARA chimera may adapt a different conformation that renders it more prone to aggregation than PML or RARa expressed from non-rearranged genes. Because of its highly insoluble conformation, the PML/RARA oncprotein may be subjected to clearance by the same or similar mechanisms that degrade other types of misfolded or aggregation-prone proteins in the cell. Consistent with this, cytoplasmic PML/RARA-containing particles formed by ectopic expression of PML/RARA and cytoplasmic PML-positive structures in NB4 cells were found to colocalize with ubiquitin, p62, and LC3, which are involved in autophagy-dependent degradation of protein aggregates. p62 contains a ubiquitin-binding domain and an LC3-interacting region and is therefore able to link ubiquitinated cargo to the core autophagic machinery. Because autophagy is a cytoplasmic degradation mechanism, proteolytic clearance of this oncprotein also occurs in the cytoplasm, in addition to its aforementioned degradation via the nuclear compartment. It supports the notion that ubiquitin is a signal for autophagic degradation of PML/RARA. Interestingly, a cytoplasmic compartment referred to as cytoplasmic assemblies of PML and nucleoporins, which appears after mitotic cell division and contains PML or PML/RARA, was cleared from NB4 cells in the presence of all-trans retinoic acid, suggesting a possible link between the stability of these cytoplasmic structures and autophagic activity.

Arsenic trioxide is a potent inducer of autophagy in acute leukemia cells, and such induction is dependent on activation of the MEK/ERK pathway but uncoupled from JNK. Experiments using chloroquine, a pharmacologic autophagy inhibitor, revealed that the inhibitory effects of arsenic trioxide on primary leukemic progenitors are mediated in part via induction of autophagic cell death. The critical role of autophagy in the anti-leukemic effects of arsenic trioxide was further established by experiments in which key elements of the autophagic pathway, such as Beclin1 and Atg7, were knocked down by using RNA interference. Previous evidence shows that in addition to apoptosis, arsenic trioxide induces autophagy in the human lymphocytic leukemia cell line Molt-4. Indeed, the catabolism of the PML/RARA oncprotein is largely affected by autophagy, and its degradation in cells treated with arsenic trioxide or all-trans retinoic acid depends upon and relates with increased autophagic activity. Autophagy also has a stimulatory role on the differentiation of NB4 APL cells, suggesting that this degradation pathway potentiates therapy-induced differentiation of APL cells. This observation supports our previous finding that autophagy is essential for vitamin D3-induced differentiation of leukemia cells.

Autophagy also plays a critical role in the anti-leukemic effects of arsenic trioxide in primary hematopoietic progenitors from AML patients. Emerging evidence suggests that treating malignant cells with arsenic trioxide results in negative feedback activation of...
cellular pathways that counteract apoptosis, implicating autophagy as a mechanism for the suppressive effects of arsenic trioxide on primitive leukemic progenitors. The findings of this study raise the potential that agents promoting autophagy can sensitize leukemia cells to the suppressive effects of arsenic trioxide [38]. Autophagic death of acute lymphoblastic lymphoma cells treated with dexamethasone was recently shown to be dependent on the PML protein, which is known to inhibit mammalian target of rapamycin (mTOR) activity. Thus, mTOR-regulated autophagy may play a general role in the development and treatment of leukemia. Previous studies show that the ubiquitin-proteasome system facilitates clearance of PML/RARα induced by all-trans retinoic acid and arsenic trioxide. Autophagy and proteasome-dependent degradation may thus cooperate in therapy-induced clearance of the APL-associated oncoprotein [5]. In line with this finding, proteolytic cross-talk has been reported to clearly exist between the autophagy and ubiquitin-proteasome systems [39].

Furthermore, proteolytic degradation of PML/RARα by caspases and lysosomal proteases has also been reported, suggesting the existence of multiple proteolytic pathways with a potential to target PML/RARα for degradation. However, because autophagy appears to become markedly induced in the presence of all-trans retinoic acid and arsenic trioxide, this degradation pathway may have a determinant role in therapy-induced PML/RARα clearance. Thus, both all-trans retinoic acid and arsenic trioxide induce clinical remission in APL patients by stimulating mTOR-dependent autophagy and causing concomitant autophagic degradation of the APL-associated oncoprotein PML/RARα [5].

Consistent with the above observations, a recent report indicated that autophagy regulates leukemic myeloid cell differentiation via p62/SQSTM1-mediated degradation of PML/RARα oncoprotein [40]. PML/RARα has been shown to enhance constitutive autophagic activity through inhibition of the Akt/mTOR signaling pathway [41].

**Autophagy in Response to Therapy for t(11;17)-Positive APL**

Another APL-specific fusion protein, the t(11;17)-associated PLZF/RARα, causes a different subtype of human APL. Patients with APL positive for t(11;17) do not respond to treatment with either all-trans retinoic acid or arsenic trioxide [42-46]. However, whether activation of autophagy is essential to degrade the PLZF/RARα fusion protein is unknown. APL patients who undergo all-trans retinoic acid monotherapy may eventually suffer relapse, as all-trans retinoic acid is apparently unable to eradicate the leukemic population. In normal hematopoiesis, all-trans retinoic acid not only induces differentiation of committed myeloid cells but may also enhance the self-renewal capabilities of stem cells and progenitors [47,48]. Therefore, all-trans retinoic acid has dual effects on the APL leukemic cell population: induction of differentiation in the mature blast population, resulting in a complete remission, and conversely, induction of proliferation and/or self-renewal of leukemic stem cells. These dual effects probably explain the failure to achieve complete molecular remission and the tendency for relapse after all-trans retinoic acid monotherapy. In contrast, arsenic trioxide can induce complete molecular remission and does not seem to exert any toxic effects on hematopoietic stem cells.

Paradoxically, all-trans retinoic acid-induced up-regulation of Beclin1 has been reported to prolong the life span of differentiated acute promyelocytic leukemia cells [49], whereas down-regulation of autophagy by siRNA-mediated knockdown of S100A8 enhanced arsenic trioxide-induced leukemia cell death [50]. These two observations suggest opposing roles of autophagy in arsenic trioxide treatment on leukemia.

**Autophagy in Response to Therapy for Leukemia That Does Not Express Known Oncoproteins**

In AML cell lines lacking known oncoprotein expression, activation of autophagy can also cause leukemia cell demise. 1,25-Dihydroxyvitamin D₃, the hormonally active form of vitamin D₃, was also tried in leukemia therapy. Vitamin D₃ inhibits cancer cell proliferation by inducing differentiation. These effects are dependent on Akt down-regulation, vitamin D₃ disassociation with Raf1, and subsequent activation of Raf/MEK/ERK2 MAPK signaling. In turn, cyclin-dependent kinase inhibitors are up-regulated, and retinoblastoma protein undergoes dephosphorylation and binding to transcription factors E2F1 and C/EBPα [51-53]. The vitamin D₃ analog EB1089 was initially reported to be able to induce apoptosis via a p53-independent mechanism involving p38 MAPK activation and ERK MAPK inactivation in B-cell chronic lymphocytic leukemia cells [54]. More recent studies showed that EB1089 triggered autophagy in breast cancer cells [55], again suggesting that the anticancer effects of the same compound may vary depending on cell types. Although vitamin D₃ shows promise in counteracting tumors, significant supraphysiologic concentration of this compound is required for antineoplastic effects. Such concentrations are not achievable in patients due to predictable hypercalcemia and hypercalcuria resulting from the increased intestinal absorption of calcium and the calcium-mobilizing properties of vitamin D₃. To reduce the risk of vitamin D₃-induced hypercalcemia and
the possible immunosuppressive effects of its analogs, a combination of low-dose vitamin D3 or its analogs with another non-immunosuppressive agent that enhances differentiation but not the levels of circulating calcium has been pursued. For example, combinations of vitamin D3 with docetaxel, dexamethasone, paclitaxel, carboplatin, and carnosic acid were tried in several types of cancers and cancer model cell lines\[15\]. However, the current combinatorial therapies with vitamin D3 in the preclinical stage are restricted to differentiation effects, thus limiting the efficacy on cancer cell suppression. A better understanding of the mechanisms by which vitamin D3 exerts suppressive effects on tumor cells is needed to develop vitamin D3 analogs and combinatorial therapies with better antineoplastic effects. We showed that vitamin D3 triggers autophagic death by up-regulating Beclin1 and triggering differentiation but inhibiting apoptosis in myeloid leukemia cells. Knockdown of Beclin1 not only crippled vitamin D3-induced autophagy but also inhibited vitamin D3-induced differentiation and activated apoptotic signaling. These data suggest that autophagy is linked to differentiation and apoptosis. We further demonstrated that additional up-regulation of autophagy dramatically improved the antineoplastic effect of vitamin D3 on human myeloid leukemia cells, suggesting a better strategy for combating leukemia\[13\].

A number of chemical compounds including arsenic trioxide\[21,35,38,40,50\], vitamin D3 \[13\], vitamin K2 \[59\], eupalinin A (sesquiterpene lactone) \[60\], BAY11-7082 (NF-κB inhibitor) \[61\], morphinone (a morphin derivative) \[62\], APO866 (NAD biosynthesis inhibitor) \[63\], and platonin \[64\] have been reported to be able to induce leukemia cell death via activation of autophagy (Table 1).

**Table 1. Autophagy-Inducing agents in acute myeloid leukemia therapy**

| Compound | Cell line | Mechanism | Cell fate | Reference(s) |
|----------|-----------|-----------|-----------|--------------|
| Arsenic trioxide | NB4 | Autophagic degradation of oncogenic fusion protein | Autophagy mediates cell death | [21,35,38,40,50] |
| Vitamin D3 | HL-60 | Up-regulation of mTOR | Autophagy mediates cell death | [13] |
| Vitamin K2 | HL-60 | Unknown | Autophagy mediates cell death | [58] |
| Eupalinin A | HL-60 | ROS generation and mitochondrial dysfunction | Autophagy mediates cell death | [59] |
| BAY11-7082 (NF-κB inhibitor) | U937 cell line, primary cells | NF-κB signaling | Autophagic stress proceeds apoptotic cell death | [60] |
| Morphinone | HL-60 cell line | Unknown | 3-MA blocks morphinone-induced cell death | [61] |
| APO866 (NAD biosynthesis inhibitor) | NB4, HL-60 | Unknown | Autophagy mediates cell death | [62] |
| Platonin | NB4, HL-60, U937 | BNIP3 overexpression | 3-MA blocks platonin-induced cell death | [63] |

**Concluding Remarks**

Studies on autophagy in leukemia have been limited to *in vitro* leukemia cell models derived from leukemia patients, and there are still few publications on autophagy in early leukemogenesis. Autophagy is a highly context-dependent process that serves different functions in leukemia and solid cancers. In solid tumors, maintaining nutrient supply is difficult, and autophagy serves as an adaptive survival mechanism for the adverse nutrient supply circumstances. However, in leukemia cells in the blood that do not face a nutrient supply challenge, enhanced activation of autophagy degrades oncogenic fusion proteins to promote terminal differentiation or “over-eats” subcellular organelles to cause autophagic cell death. Despite its observed role in the development and maintenance of cancer in animal models and its opposing effects in response to a wide array of cancer therapies, autophagy in human AML cells predominantly drives a cytotoxic cascade that induces clearance of oncogenic fusion proteins and leads to cell death. Thus, autophagy may be a new strategy for targeted perturbation of oncogenic proteins in certain type of acute myeloid leukemia. A recent study also showed that autophagy is essential to maintain normal hematopoietic stem cell function in quiescence, self-renewal, and multilineage differentiation\[64\]. The autophagy pathway in stem cells may thus restrain transformation and prevent cancer by removing free radicals and limiting damage within stem cells, thereby
protecting normal stem cells from germination of leukemia. Future strategies for tackling leukemogenesis may focus more on the early prevention of transformation at hematopoietic stem cell level.

Acknowledgment

This work was supported by grants from National Science Foundation of China (No. 31071258), The Ministry of Science and Technology of China (Pre-973 Plan: No. 2011CB512101; 863 Plan: No. 2011AA020114), and a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).

Received: 2012-03-27; revised: 2012-06-17; accepted: 2012-06-29.

References

[1] Cole A, Ricci JE, Tait S, et al. GAPDH and autophagy preserve survival after apoptotic cytochrome c release in the absence of caspase activation. Cell, 2007,129:983–997.
[2] Iwata J, Ezaki J, Komatsu M, et al. Excess peroxisomes are degraded by autophagic machinery in mammals. J Biol Chem, 2006,281:4035–4041.
[3] Mathew R, Kongara S, Beaudoin B, et al. Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev, 2007,21:1367–1381.
[4] Mathew R, Karp CM, Beaudoin B, et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell, 2009,137:1062–1075.
[5] Pankiv S, Clausen TH, Lamark T, et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem, 2007,282:24131–24145.
[6] Lunn JJ, DeBerardinis RJ, Thompson CB. Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol, 2005,6:439–448.
[7] Altman BJ, Wofford JA, Zhao Y, et al. Autophagy provides nutrients but can lead to chop-dependent induction of Bim to sensitize growth factor deprived cells to apoptosis. Mol Biol Cell, 2009,20:1180–1191.
[8] Singh R, Kaushik S, Wang Y, et al. Autophagy regulates lipid metabolism. Nature, 2008,458:1131–1135.
[9] Bursch W, Hochegger K, Torok L, et al. Autophagic and apoptotic types of programmed cell death exhibit different fates of cytoskeletal filaments. J Cell Sci, 2000,113:1189–1198.
[10] Inbal B, Blialk S, Sabanay I, et al. DAP kinase and DRP-1 mediate membrane blebbing and the formation of autophagic vesicles during programmed cell death. J Cell Biol, 2002,157:465–468.
[11] Paglin S, Hollister T, Delohery T, et al. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res, 2001,61:439–444.
[12] Hoyer-Hansen M, Baathlom L, Mathisen S, et al. Vitamin D analog EB1089 triggers dramatic lysosomal changes and Beclin1-mediated autophagic cell death. Cell Death Differ, 2005,12:1297–1309.
[13] Wang J, Lian H, Zhao Y, et al. Vitamin D3 induces autophagy of human myeloid leukemia cells. J Biol Chem, 2008,283:26596–26605.
[14] Liang XH, Jackson S, Seaman M, et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature, 1999,402:672–676.
[15] Yue Z, Jin S, Yang C, et al. Beclin 1, an autophagy gene essential for early embryonic development, is a haptinsufficient tumor suppressor. Proc Natl Acad Sci USA, 2003,100:15077–15082.
[16] Degeshardt K, Mathew R, Beaudoin B, et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell, 2006,10:51–64.
[17] Jin S, White E. Role of autophagy in cancer: management of metabolic stress. Autophagy, 2007,3:28–31.
[18] Karantza-Wadsworth V, Patel S, Kravchuk O, et al. Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev, 2007,21:1621–1635.
[19] Tenen DG. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer, 2003,3:89–101.
[20] Jordan CT, Guzman ML. Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene, 2004,23:7175–7187.
[21] Zheng X, Seshare A, Ruster B, et al. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARα-positive stem cells. Haematologica, 2007,92:323–331.
[22] Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood, 1998,82:567–572.
[23] Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood, 1999,93:3167–3215.
[24] Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukaemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARalpha/PML proteins. Blood, 1996,88:1052–1061.
[25] Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood, 1997,89:3345–3353.
[26] Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. clinical efficacy and pharmacokinetics in relapsed patients. Blood, 1997,89:3354–3360.
[27] Lallemand-Breitenbach V, Jeanne M, Benhenda S, et al. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol, 2008,10:547–555.
[28] Talham MH, Geoffrey MC, Shen L, et al. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol, 2008,10:538–546.
[29] Zhang XW, Yan XJ, Zhou ZR, et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science, 2010,328:240–243.
[30] Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA, 2004,101:5326–5335.
[31] Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of all-trans retinoic acid/arsen trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A, 2009;106:3342–3347.

[32] Shen TH, Lin HK, Scaglioni PP, et al. The mechanisms of PML-nuclear body formation. Mol Cell, 2006;24:331–339.

[33] Bernardi R, Pandolfi PP. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol, 2007;8:1006–1016.

[34] Lamark T, Kirkin V, Dikic I, et al. NBR1 and p62 as cargo receptors for selective autophagy of ubiquitinated targets. Cell Cycle, 2009;8:1986–1990.

[35] Isakson P, Bjoras M, Boe SO, et al. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. Blood, 2010;116:2304–2311.

[36] Song J, Qu Z, Guo X, et al. Hypoxia-induced autophagy contributes to the chemoresistance of hepatocellular carcinoma cells. Autophagy, 2009;5:1131–1144.

[37] Giani W, Liu J, Jin J, et al. Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin1. Leuk Res, 2007;31:329–339.

[38] Goussetis DJ, Altman JK, Glaser H, et al. Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide. J Biol Chem, 2010;285:29989–29997.

[39] Nedelsky NB, Todd PK, Taylor JP. Autophagy and the ubiquitin-proteasome system: collaborators in neuroprotection. Biochim Biophys Acta, 2008;1782:691–699.

[40] Wang Z, Cao L, Kang R, et al. Autophagy regulates myeloid cell differentiation by p62/SQSTM1-mediated degradation of PML-RARA oncoprotein. Autophagy, 2011;7:404–411.

[41] Huang Y, Hou JK, Chen TT, et al. PML-RARA enhances constitutive autophagic activity through inhibiting the Akt/mTOR pathway. Autophagy, 2011;7:1132–1144.

[42] Chen Z, Brand NJ, Chen A, et al. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant (11;17) translocation associated with acute promyelocytic leukaemia. EMBO J, 1993;12:1161–1167.

[43] Licht JD, Chomienne C, Goy A, et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood, 1996;85:1083–1094.

[44] Ruthardt M, Testa U, Nervi C, et al. Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (PML-RARα) and PLZF-RARα fusion proteins on retinoic acid signaling. Mol Cell Biol, 1997;17:4859–4869.

[45] Kokan MH, Daniel MT, Gianni M, et al. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17) (q25;q21) APL patient. Oncogene, 1999;18:1113–1118.

[46] Sternsdorf T, Puccetti E, Jensen K, et al. PIC-1/SUMO-1-modified PML retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol Cell Biol, 1999;19:5170–5178.

[47] Collins SJ. The role of retinoids and retinoic acid receptors in normal hematopoiesis. Leukemia, 2002;16:1896–1905.

[48] Bug G, Gul H, Schwarz K, et al. Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res, 2005;65:2537–2541.

[49] Troccoli A, Mathieu J, Priault M, et al. ATRA-induced upregulation of Beclin1 prolongs the life span of differentiated acute promyelocytic leukemia cells. Autophagy, 2011;7:1108–1114.

[50] Yang L, Yang M, Zhang H, et al. S100A8-targeting siRNA enhances arsenic trioxide-induced myeloid leukemia cell death by down-regulating autophagy. Int J Mol Med, 2012;29:65–72.

[51] Breitkreutz I, Raab MS, Vallet S, et al. Targeting MER1/2 blocks osteoclast differentiation function and cytokine secretion in multiple myeloma. Br J Haematol, 2012;159:2083–2088.

[52] Capaldi D A, Rossi AM, Picotto G, et al. Inhibition of serum-stimulated mitogen activated protein kinase by 1alpha,25(OH)2-vitamin D3 in MCF-7 breast cancer cells. J Cell Biochem, 2004;93:384–397.

[53] Wang J, Zhao Y, Kauss MA, et al. Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling. Eur J Cell Biol, 2009;88:103–115.

[54] Pepper C, Thomas A, Hoy T, et al. The vitamin D3 analog EB1089 induces apoptosis via p38-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro. Blood, 2003;101:2454–2460.

[55] Beer TM, Eilers KM, Garzotto M, et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol, 2003;21:128–138.

[56] Beer TM, Ryan CW, Venner PM. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT investigators. J Clin Oncol, 2007;25:669–674.

[57] Danilenko M, Wang X, Studzinski GP. Carnosic acid and promotion of monocytic differentiation of HL-60 cells initiated by other agents. J Natl Cancer Inst, 2001;93:1224–1233.

[58] Yokoyama T, Miyazaka K, Naito M, et al. Vitamin K2 induces autophagy and apoptosis simultaneously in leukemia cells. Autophagy, 2008;4:629–640.

[59] Itcho T, Oghuchi K, Nozawa Y, et al. Intracellular glutathione regulates sequiterpene lactone-induced conversion of autophagy to apoptosis in human leukemia HL-60 cells. Anticancer Res, 2009;29:1449–1457.

[60] Fabre C, Carvalho G, Tasdemir E, et al. NF-κB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene, 2007;26:4071–4083.

[61] Takeuchi R, Hoehjima H, Nagasaaka H, et al. Induction of non-apoptotic cell death by morphine in human promyelocytic leukemia HL-60 cells. Anticancer Res, 2006;26:3343–3348.

[62] Nahimana A, Attinger A, Aubry D, et al. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood, 2009;113:3276–3286.

[63] Chen YJ, Huang WP, Yang YC, et al. Platinin induces autophagy-associated cell death in human leukemia cells. Autophagy, 2009;5:173–183.

[64] Mortensen M, Watson AS, Simon AK. Lack of autophagy in the hematopoetic system leads to loss of hematopoietic stem cell function and dysregulated myeloid proliferation. Autophagy, 2011;7:1069–1070.